NCT06814730 · Phase 1 · RECRUITING
A Study to Assess THN391 in Subjects With Alzheimer's Disease
This trial is testing THN391, a new drug, in people with early Alzheimer's disease who also have a condition called cerebral small vessel disease — meaning small blood vessels in the brain show signs of damage. It is a Phase 1b trial, which means the focus right now is on safety and how the drug behaves in the body, not yet on whether it actually works. Three monthly doses are given over about six months, with MRI scans and spinal taps included.
You may qualify if
- Be willing and able to understand the study procedures and the risks involved and provide written informed consent before the first study-related activity
- 65 to 85 years of age (inclusive at the time of informed consent).
- Diagnosis of Early Alzheimer's Disease (AD)
- Diagnosis of cerebral Small Vessel Disease (cSVD), and having at least one of the following vascular risk factors: hypertension, Type 2 diabetes mellitus, or hyperlipidemia
You're excluded if
- Diagnosis of moderate or severe dementia
- Any other medical condition except for early AD (e.g. any clinically significant neurological, psychiatric or large vessel disease) that could affect interpretation of study assessments
- Use of anticoagulant, except for either clopidogrel or low dose aspirin, unless taken simultaneously
The sponsor's own eligibility wording, lightly reformatted. The study team makes the final eligibility decision — worth discussing with your doctor.
Eligibility criteria as of 2025-09-11